JP7071981B2 - 疾患の治療のための二置換ピラゾール化合物 - Google Patents

疾患の治療のための二置換ピラゾール化合物 Download PDF

Info

Publication number
JP7071981B2
JP7071981B2 JP2019533314A JP2019533314A JP7071981B2 JP 7071981 B2 JP7071981 B2 JP 7071981B2 JP 2019533314 A JP2019533314 A JP 2019533314A JP 2019533314 A JP2019533314 A JP 2019533314A JP 7071981 B2 JP7071981 B2 JP 7071981B2
Authority
JP
Japan
Prior art keywords
compound
cancer
formula
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530742A5 (https=
JP2019530742A (ja
Inventor
志成 上杉
キンケイド ジョン
ハフ ジョエル
Original Assignee
エフジーエイチ バイオテック，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフジーエイチ バイオテック，インコーポレーテッド filed Critical エフジーエイチ バイオテック，インコーポレーテッド
Publication of JP2019530742A publication Critical patent/JP2019530742A/ja
Publication of JP2019530742A5 publication Critical patent/JP2019530742A5/ja
Application granted granted Critical
Publication of JP7071981B2 publication Critical patent/JP7071981B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019533314A 2016-09-07 2017-09-07 疾患の治療のための二置換ピラゾール化合物 Active JP7071981B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662384661P 2016-09-07 2016-09-07
US62/384,661 2016-09-07
US201662438944P 2016-12-23 2016-12-23
US62/438,944 2016-12-23
PCT/US2017/050562 WO2018049080A1 (en) 2016-09-07 2017-09-07 Di-substituted pyrazole compounds for the treatment of diseases

Publications (3)

Publication Number Publication Date
JP2019530742A JP2019530742A (ja) 2019-10-24
JP2019530742A5 JP2019530742A5 (https=) 2021-01-28
JP7071981B2 true JP7071981B2 (ja) 2022-05-19

Family

ID=59895438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533314A Active JP7071981B2 (ja) 2016-09-07 2017-09-07 疾患の治療のための二置換ピラゾール化合物

Country Status (7)

Country Link
US (1) US11339142B2 (https=)
EP (1) EP3510027B1 (https=)
JP (1) JP7071981B2 (https=)
CN (1) CN110072861B (https=)
AU (1) AU2017323521B9 (https=)
ES (1) ES2932187T3 (https=)
WO (1) WO2018049080A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328064B2 (en) 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
KR102498741B1 (ko) * 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
ES2932187T3 (es) 2016-09-07 2023-01-16 Fgh Biotech Inc Compuestos de pirazol disustituidos para el tratamiento de enfermedades
CN108947839A (zh) * 2018-06-28 2018-12-07 山东润博生物科技有限公司 一种苯氧羧酸类除草剂的制备方法
CN108947841A (zh) * 2018-06-28 2018-12-07 山东润博生物科技有限公司 一种苯氧羧酸酯的制备方法
CN109265352B (zh) * 2018-10-31 2021-06-04 杭州迈世腾药物科技有限公司 芳基环丙基醚及其衍生物的制备方法
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
EP4096659A4 (en) * 2020-01-27 2023-10-18 Capulus Therapeutics, LLC Srebp inhibitors comprising a thiophene central ring

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
WO2005063737A1 (ja) 2003-12-26 2005-07-14 Daiichi Pharmaceutical Co., Ltd. アミドピラゾール誘導体
JP2006514095A (ja) 2002-12-02 2006-04-27 アステラス製薬株式会社 ピラゾール誘導体
JP2006525320A (ja) 2003-05-08 2006-11-09 アステラス製薬株式会社 Ｃｏｘ阻害剤
JP2008528700A (ja) 2005-02-03 2008-07-31 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｐａｒモジュレーターとしての化合物および組成物
JP2010519181A (ja) 2007-02-02 2010-06-03 ベイラー カレッジ オブ メディスン 代謝障害を処置するための組成物および方法
US20150065519A1 (en) 2013-08-28 2015-03-05 Medivation Technologies, Inc. Heterocyclic compounds and methods of use

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
CZ284157B6 (cs) 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP3303044B2 (ja) 1994-12-21 2002-07-15 エヌイーシートーキン株式会社 永久磁石とその製造方法
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6130217A (en) 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
ATE407132T1 (de) 2000-12-05 2008-09-15 Vertex Pharma Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
AU2003216581A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
CA2489335C (en) 2002-05-22 2012-07-10 Groep Stevens International, Naamloze Vennootschap Tufted composite laminate
AU2002953019A0 (en) * 2002-12-02 2002-12-12 Fujisawa Pharmaceutical Co., Ltd. Azole derivatives
RU2005134670A (ru) 2003-04-10 2006-06-10 Аванир Фармасьютикалс (Us) Производные имидазола для лечения аллергических и гиперпролиферативных нарушений
WO2005044194A2 (en) 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
EP1789498A1 (en) 2004-09-02 2007-05-30 Clariant International Ltd. Use of thiazolyl-pyridinium dyes for optical data recording
EP2402323A3 (en) 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
CN101203220A (zh) 2005-06-28 2008-06-18 阿斯利康(瑞典)有限公司 新用途
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US20160221999A1 (en) 2007-02-02 2016-08-04 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9085566B2 (en) 2007-02-02 2015-07-21 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and related disorders
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
DE102007040243A1 (de) 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
CN101918389A (zh) 2007-11-02 2010-12-15 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
TWI453019B (zh) 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物
GB0806794D0 (en) 2008-04-15 2008-05-14 Ludwig Inst Cancer Res Therapeutic compounds
JP5640091B2 (ja) 2009-10-01 2014-12-10 カディラ・ヘルスケア・リミテッド 脂質異常症および関連疾患の治療のための化合物
CN102933079B (zh) * 2010-03-04 2016-02-17 默沙东公司 儿茶酚-o-甲基转移酶抑制剂及其在治疗精神障碍中的用途
WO2011133444A1 (en) 2010-04-21 2011-10-27 Merck Sharp & Dohme Corp. Substituted pyrimidines
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
EP2755962B1 (en) 2011-09-13 2017-03-01 Glaxosmithkline LLC Azaindazoles
BR112014006940A2 (pt) 2011-09-23 2017-04-04 Bayer Ip Gmbh uso de derivados de ácido 1-fenilpirazol-3-carboxílico 4-substituído como agentes contra estresse abiótico em plantas
WO2015031710A1 (en) * 2013-08-29 2015-03-05 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and body weight related disorders
AU2014345594B2 (en) 2013-11-05 2018-11-08 Elanco Animal Health Gmbh Substituted benzamides for the treatment of arthropods
EP3096761A1 (en) 2014-01-24 2016-11-30 Confluence Life Sciences, Inc. Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
WO2016073826A1 (en) 2014-11-07 2016-05-12 Fgh Biotech, Inc. Synthesis of fatostatin based polycyclic compounds
AU2015369712B2 (en) 2014-12-22 2020-05-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mutant IDH1 inhibitors useful for treating cancer
BR112017005650A2 (pt) 2014-12-22 2018-01-23 Halliburton Energy Services Inc método para tratar uma formação subterrânea, sistema para realizar o método para tratar uma formação subterrânea, composição para o tratamento de uma formação subterrânea e método para preparar uma composição para o tratamento de uma formação subterrânea
US10328064B2 (en) 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
US10183015B2 (en) 2015-03-04 2019-01-22 Medivation Technologies Llc Heterocyclic compounds and methods of use
EP3265457A1 (en) 2015-03-04 2018-01-10 Medivation Technologies LLC Sterol regulatory element-binding proteins (srebps) inhibitors
CN105294584A (zh) 2015-11-30 2016-02-03 中国医科大学 1-取代苯基-1h-1,2,3-三唑类化合物、制备方法及其用途
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
ES2932187T3 (es) 2016-09-07 2023-01-16 Fgh Biotech Inc Compuestos de pirazol disustituidos para el tratamiento de enfermedades

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514095A (ja) 2002-12-02 2006-04-27 アステラス製薬株式会社 ピラゾール誘導体
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006525320A (ja) 2003-05-08 2006-11-09 アステラス製薬株式会社 Ｃｏｘ阻害剤
WO2005063737A1 (ja) 2003-12-26 2005-07-14 Daiichi Pharmaceutical Co., Ltd. アミドピラゾール誘導体
JP2008528700A (ja) 2005-02-03 2008-07-31 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｐａｒモジュレーターとしての化合物および組成物
JP2010519181A (ja) 2007-02-02 2010-06-03 ベイラー カレッジ オブ メディスン 代謝障害を処置するための組成物および方法
US20150065519A1 (en) 2013-08-28 2015-03-05 Medivation Technologies, Inc. Heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
CN110072861A (zh) 2019-07-30
US20190194167A1 (en) 2019-06-27
US11339142B2 (en) 2022-05-24
ES2932187T3 (es) 2023-01-16
AU2017323521A1 (en) 2019-05-02
WO2018049080A1 (en) 2018-03-15
EP3510027A1 (en) 2019-07-17
AU2017323521B2 (en) 2021-11-11
CN110072861B (zh) 2022-11-11
AU2017323521B9 (en) 2022-02-17
CA3036195A1 (en) 2018-03-15
EP3510027B1 (en) 2022-11-02
JP2019530742A (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
JP7071981B2 (ja) 疾患の治療のための二置換ピラゾール化合物
JP6931695B2 (ja) 疾患の治療のための二置換ピラゾール化合物
TWI501949B (zh) 硫乙酸酯／鹽組合物及其使用方法
TWI694076B (zh) 三唑并嘧啶化合物及其用途
EP4039675B1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
CN111065393B (zh) 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物
CN106432229B (zh) 一类用于治疗或预防高尿酸血症或痛风的化合物
DK3046902T3 (en) COMPOSITIONS FOR TREATING HYPERTENSION AND / OR FIBROSE
CN111093658A (zh) 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物
RU2772212C2 (ru) Двухзамещенные соединения пиразола для лечения заболеваний
TW201818964A (zh) 使用色胺酸羥化酶抑制劑之方法
CA3036195C (en) Di-substituted pyrazole compounds for the treatment of diseases
EP4397654A1 (en) Ep4 antagonist compound as well as salt, polymorph, and use thereof
HK40079392B (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
HK40079392A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
JP2025111552A (ja) 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用
WO2026021557A1 (zh) 苯并吲哚衍生物的药物组合物、制备方法及用途
WO2014003158A1 (ja) インドール誘導体又はその塩

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220509

R150 Certificate of patent or registration of utility model

Ref document number: 7071981

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250